QIAGEN Expands QIAstat-Dx Operations with New Barcelona Site
QIAGEN is relocating its QIAstat-Dx operations to a new facility in Barcelona to strengthen its syndromic testing capabilities.
Read MorePosted by Andy Lundin | Dec 2, 2024 | Company News |
QIAGEN is relocating its QIAstat-Dx operations to a new facility in Barcelona to strengthen its syndromic testing capabilities.
Read MorePosted by Andy Lundin | Dec 2, 2024 | Molecular Diagnostics, Unknown Origin & Other Cancer Types |
Mission Bio’s collaboration will leverage single-cell DNA analysis for insights into multiple myeloma relapse and treatment strategies.
Read MorePosted by Chris Wolski | Nov 27, 2024 | Covid 19 |
Investigators have developed an AI tool to analyze electronic health records, helping clinicians identify cases of long COVID.
Read MorePosted by Andy Lundin | Nov 25, 2024 | Company News |
The CLIA-certified lab launched a pharmacogenetic assay to empower tailored treatments for psychiatric, neurological, and related conditions.
Read MorePosted by Andy Lundin | Nov 22, 2024 | Molecular Diagnostics |
A new study shows how genetic testing could personalize postoperative pain management by identifying genetic predispositions to opioid use.
Read More